Freya Biosciences named one of Fierce Biotech’s “Fierce 15” for 2026Read more
Freya Biosciences is a clinical-stage immunology company developing therapies to address inflammation and immune dysregulation in conditions affecting women.
Our approach
Freya focuses on the underlying drivers of disease, not just symptoms.
By targeting immune mechanisms, we aim to restore healthy biological function and improve clinical outcomes for patients.
Addressing a major unmet need
Women’s health remains a significantly underserved area of medicine. Freya develops disease-modifying therapies where the need for effective solutions is urgent and the opportunity to improve therapeutic care for patients is substantial.
~1 in 10
couples face infertility and undergo more than 2.5 million IVF cycles per year
1 in 4
women have dysbiosis during pregnancy, increasing the risk for preterm birth
1 in 10
babies are born premature, and ~1 million die each year
Addressing a major unmet need
Women’s health remains a significantly underserved area of medicine. Freya develops disease-modifying therapies where the need for effective solutions is urgent and the opportunity to improve therapeutic care for patients is substantial.
~1 in 10
couples face infertility and undergo more than 2.5 million IVF cycles per year
1 in 4
women have dysbiosis during pregnancy, increasing the risk for preterm birth
1 in 10
babies are born premature, and ~1 million die each year
Freya’s strategy moves beyond symptom relief to address root immunological causes of conditions such as infertility, preterm birth and others such as endometriosis.
Copyright © Freya
